Abstract | BACKGROUND: CASE PRESENTATION: A 41-year-old Japanese male with right ischiac pain was diagnosed with a giant cell tumor in his right ischium. Since the tumor extended to the acetabulum, there was a possibility that en bloc resection might significantly impair function of the hip joint and curettage could cause massive bleeding. Therefore, denosumab therapy (120 mg, administered 3 times every 4 weeks) was performed before radical surgery. The giant cell tumor of bone was treated with denosumab successfully. No adverse reaction was noted. Tartrate-resistant acid phosphatase 5b secretion was measured in the patient's serum to monitor the response to denosumab, and a rapid normalization of the marker was observed after the first denosumab administration. CONCLUSION:
|
Authors | Naoto Watanabe, Seiichi Matsumoto, Takashi Shimoji, Keisuke Ae, Taisuke Tanizawa, Tabu Gokita, Noriko Motoi, Teruko Ueno, Mitsuru Koizumi |
Journal | BMC research notes
(BMC Res Notes)
Vol. 7
Pg. 608
(Sep 05 2014)
ISSN: 1756-0500 [Electronic] England |
PMID | 25193435
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Isoenzymes
- Denosumab
- Acid Phosphatase
- Tartrate-Resistant Acid Phosphatase
|
Topics |
- Acid Phosphatase
(metabolism)
- Adult
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Bone Neoplasms
(diagnostic imaging, drug therapy, enzymology)
- Denosumab
- Giant Cell Tumor of Bone
(diagnostic imaging, drug therapy, metabolism)
- Humans
- Isoenzymes
(metabolism)
- Male
- Tartrate-Resistant Acid Phosphatase
- Tomography, X-Ray Computed
|